ReviewPsychopharmacology2014
Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.
Review in Psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Aripiprazole for treating irritability in children & adolescents with autism: A systematic review.The Indian journal of medical research · 2015Pooled it
- Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support.Translational psychiatry · 2026Trial
- Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support.medRxiv : the preprint server for health sciences · 2025Article
- A Review of Therapeutic Approaches for Autism Spectrum Disorder.Brain sciences · 2025Review
- Exploring pathological targets and advancing pharmacotherapy in autism spectrum disorder: Contributions of glial cells and heavy metals.Histology and histopathology · 2025Review
- Review
- Growing evidence of pharmacotherapy effectiveness in managing attention-deficit/hyperactivity disorder in young children with or without autism spectrum disorder: a minireview.Frontiers in psychiatry · 2024Review
- Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities.Paediatric drugs · 2022Review
- Article
- Article
- Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study.Children (Basel, Switzerland) · 2021Article
- Interest of Fluvoxamine as an Add-On to Clozapine in Children With Severe Psychiatric Disorder According to CYP Polymorphisms: Experience From a Case Series.Frontiers in psychiatry · 2021Article
- Lurasidone an Effective Alternative for the Treatment of Irritability Associated With Autism Spectrum Disorder.Cureus · 2020Article
- Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series.Neuropsychiatric disease and treatment · 2020Article
- p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Autism spectrum disorder.Lancet (London, England) · 2018Review
- 17-β estradiol increases parvalbumin levels inMolecular autism · 2018Article
- Multiple Antipsychotic Medication Use in Autism Spectrum Disorder.Journal of child and adolescent psychopharmacology · 2017Article
- Evaluation of the Safety of Quetiapine in Treating Delirium in Critically Ill Children: A Retrospective Review.Journal of child and adolescent psychopharmacology · 2015Article
- A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder.Journal of child and adolescent psychopharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleAutism and related pervasive developmental disorders (PDD) are characterized by impairments in social interaction and communication, restricted interests, and repetitive and stereotyped patterns of behavior. Individuals with PDD frequently display irritability and disruptive behaviors including tantrums, self-injurious behavior, and aggression. Atypical antipsychotics are currently the most efficacious pharmacological interventions available for treatment of irritability associated with PDD.
objectivesThis article aims to review the body of literature pertaining to the use of atypical antipsychotics in the treatment of patients with PDD.
methodsA PubMed literature search was conducted using the following key words: autism, pervasive developmental disorders, atypical antipsychotics, risperidone, aripiprazole, quetiapine, ziprasidone, olanzapine, clozapine, paliperidone, iloperidone, asenapine, and lurasidone. Search terms were limited to English language, human subjects, and publication from 1999 to present. Relevant references from identified articles were also reviewed.
resultsThe efficacy and tolerability of risperidone and aripiprazole for the treatment of irritability in autism have been established with multi-site, randomized, controlled trials. Studies supporting the use of other atypical antipsychotics are either limited in scope or less robust in their findings, though newer agents such as ziprasidone and paliperidone show promise.
conclusionsAtypical antipsychotics are currently first-line pharmacological agents for the treatment of irritability and associated behaviors in children with PDD. Further placebo-controlled studies are warranted to characterize the efficacy and tolerability of the majority of these medications. There is also a need for the development of novel, targeted drugs with more favorable long-term side effect profiles.
Indexed as
Identifiers
23552907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.